Oral treatment for canine lymphoma in the United States

Preliminary results show stabilization of the disease for at least 56 days for 29% of dogs treated with Laverdia-CA1, medication intended to be administered by the owner.

The US Food and Drug Administration (FDA) has just granted conditional marketing authorization for Laverdia-CA1 (Anivive Lifesciences laboratory), a drug in the form of tablets based on verdinexor, indicated for the treatment of canine lymphoma. This molecule is a selective inhibitor of exportin 1 (XPO1 or CRM1, SINE class for Selective Inhibitors of Nuclear Export). This type of inhibitor blocks the nuclear export of anti-oncogenic proteins, which helps restore the cells’ natural anti-tumor defenses. Laverdia-CA1 is the first oral medication indicated for lymphoma to be granted such authorization *. He can be …

This content is reserved for members of the Le Point Vétérinaire.fr site

Already have an account ?

You do not have an account

Register and take advantage of the free services offered on Le Point Vétérinaire.fr

Do you subscribe to the paper version of the Editions du Point Vétérinaire, the DMV or the ROY Directory?
Create an account to benefit from the digital version and the services included in your subscription.

Valentine Chamard

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.